Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016" report to their offering.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

This report provides comprehensive information on the therapeutic development for Glioblastoma multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma multiforme (GBM) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • AbbVie Inc
  • Activartis Biotech GmbH
  • Advanced Accelerator Applications SA
  • Advantagene Inc
  • Advenchen Laboratories LLC
  • Affimed GmbH
  • Agenus Inc
  • Amal Therapeutics SA
  • Ambrx Inc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • AngioChem Inc
  • Apac Biotech Pvt Ltd
  • Apceth GmbH & Co KG
  • APIM Therapeutics AS
  • Apogenix GmbH
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • (150+ Others)

Key Topics Covered:

  1. Introduction
  2. Glioblastoma multiforme (GBM) Overview
  3. Therapeutics Development
  4. Pipeline Products for Glioblastoma multiforme (GBM) - Overview
  5. Pipeline Products for Glioblastoma multiforme (GBM) - Comparative Analysis
  6. Glioblastoma multiforme (GBM) - Therapeutics under Development by Companies
  7. Glioblastoma multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
  8. Glioblastoma multiforme (GBM) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Glioblastoma multiforme (GBM) - Products under Development by Companies
  13. Glioblastoma multiforme (GBM) - Products under Investigation by Universities/Institutes
  14. Glioblastoma multiforme (GBM) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/j46s8k/glioblastoma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs